Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid ...
Compumedics (ASX:CMP) said the last financial year laid a stronger more scalable business model for FY26 and beyond with record sales orders of $63.4 million, up 22% on FY24. EBITDA increased to ~$3m, ...
Special Report: Compumedics has received endorsements from two equity research firms — East Coast Research and PAC Partners— both of which see upside potential in the company’s share price and strong ...
Compumedics delivers breakout performance in FY25 with record revenue and sales orders, a return to profitability, and accelerating growth in the US and SaaS segments. Compumedics (ASX:CMP) said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results